Effect of acute and chronic treatment with milnacipran potentiates the anticonvulsant activity of conventional antiepileptic drugs in the maximal electroshock-induced seizures in mice

Psychopharmacology

Volumn 207, Issue 4, 2010, Pages 661-669

  Borowicz, Kinga K ^a   Furmanek Karwowska, Kamila ^a   Morawska, Marta ^a   Luszczki, Jarogniew J ^a   Czuczwar, Stanislaw J ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Antiepileptic drugs; Maximal electroshock; Milnacipran; Pharmacokinetic interaction

Indexed keywords

CARBAMAZEPINE; MILNACIPRAN; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CHIMNEY TEST; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG POTENTIATION; ELECTRIC SHOCK; EXPERIMENTAL TEST; IMMUNOFLUORESCENCE; LONG TERM MEMORY; MALE; MEMORY DISORDER; MOTOR COORDINATION; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PASSIVE AVOIDANCE TASK; PRIORITY JOURNAL; SEIZURE;

ANIMALS; ANTICONVULSANTS; BRAIN; CYCLOPROPANES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ELECTROSHOCK; MALE; MEMORY; MICE; PSYCHOMOTOR PERFORMANCE; SEIZURES; SEROTONIN UPTAKE INHIBITORS;

EID: 72049088517     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-009-1698-x     Document Type: Article

References (58)

1. Assie MB, Charveron M, Palmier C, Puozzo C, Moret C, Briley M (1992) Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain. Neuropharmacology 31:149-155
2. Bagdy G, Kecskemeti V, Riba P, Jakus R (2007) Serotonin and epilepsy. J Neurochem 100(4):857-873
3. Boissier JR, Tardy J, Diverres JC (1960) Une nouvelle methode simple pour explorer l'action tranquilisante: le test de la cheminee. Med Exp (Basel) 3:81-84
4. Borowicz KK, Stepien K, Czuczwar SJ (2006) Fluoxetine enhances the anticonvulsant effects of conventional antiepileptic drugs in maximal electroshock seizures in mice. Pharmacol Rep 58:83-90
5. Borowicz KK, Banach M, Zarczuk R, Lukasik D, Luszczki JJ, Czuczwar SJ (2007a) Acute and chronic treatment with mianserin differentially affects the anticonvulsant activity of conventional antiepileptics drugs in the mouse maximal electroshock model. Psychopharmacology 195:167-174 (Pubitemid 350045836)
6. Borowicz KK, Furmanek-Karwowska K, Sawicka K, Luszczki JJ, Czuczwar SJ (2007b) Chronically administered fluoxetine enhances the anticonvulsant activity of conventional antiepileptics drugs in the mouse maximal electroshock model. Eur J Pharmacol 567:77-82 (Pubitemid 46782817)
7. Bourin M (1999) Psychopharmacological profile of venlafaxine. Encephale 25 Spec No 2:21-25
8. Bourin M, Masse F, Daily E, Hascoet M (2005) Anxiolytic-like effect of milnacipran in the four-plate test in mice: mechanism of action. Pharmacol Biochem Behav 81:645-656 (Pubitemid 40973787)
9. Briley M, Prost JF, Moret C (1996) Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 11 Suppl 4:9-14
10. Ceron-Litvoc D, Soares BG, Geddes J, Litvoc J, de Lima MS (2009) Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials. Hum Psychopharmacol 24:19-28
11. Ceyhan M, Kayir H, Uzbay IT (2005) Investigation of the effects of tianeptine and fluoxetine on pentylenetetrazole-induced seizures in rats. J Psychiatr Res 39:191-196 (Pubitemid 39610524)
12. Chen Z, Yang J, Tobak A (2008) Designing new treatments for depression and anxiety. I Drugs 11:189-197 (Pubitemid 351323373)
13. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y (2004) Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D and 5HT receptors. J Neurochem 89:834-843 (Pubitemid 38684731)
14. Dailey JW, Naritoku DK (1996) Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Biochem Pharmacol 52:1323-1329
15. Deak F, Lasztoczi B, Pacher P, Petheo GL, Kecskemeti V, Spat A (2000) Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells. Neuropharmacology 39:1029-1036 (Pubitemid 30155710)
16. Favale E, Rubino V, Mainardi P, Lunardi G, Albano C (1995) Anticonvulsant effect of fluoxetine in humans. Neurology 45:1926-1927
17. Haddad PM, Das A, Ashfaq M, Wieck A (2009) A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol 5:539-551
18. Harden CL, Goldstein MA (2002) Mood disorders in patients with epilepsy: epidemiology and management. CNS Drugs 16:291-302 (Pubitemid 34548197)
19. Holmes GL (2007) Animal model studies application to human patients. Neurology 69(Suppl 3):S28-S32 (Pubitemid 350294670)
20. Ivanez V, Ojeda J (2006) Exacerbation of seizures in medial temporal lobe epilepsy due to an alpha1-adrenergic antagonist. Epilepsia 47:1741-1742 (Pubitemid 44556410)
21. Ivkovic M, Damjanovic A, Jovanovic A, Cvetic T, Jasovic-Gasic M (2009) Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability. Psychiatr Danub 21:187-193
22. Jobe PC (2003) Common pathogenic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy Behav 4: S14-S24 (Pubitemid 37428233)
23. Jobe CJ, Browning RA (2005) The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav 7:602-619
24. Jobe PC, Dailey JW, Wernicke JF (1999) A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit Rev Neurobiol 13:317-356
25. Juruena MF, Ottoni GL, Machado-Vieira R, Carneiro RM, Weingarthner N, Marquardt AR, Fleig SS, Broilo L, Busnello EA (2009) Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 33:94-99
26. Kleinrok Z, Gustaw J, Czuczwar SJ (1991) Influence of antidepressant drugs on seizure susceptibility and the anticonvulsant activity of valproate in mice. J Neural Transm (Suppl.) 34:85-90
27. Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99-113
28. Luszczki JJ, Czuczwar SJ (2005) How significant is the difference between drug doses influencing the threshold for electroconvulsions? Pharmacol Rep 57:782-786
29. Meurs A, Clinckers R, Ebinger G, Michotte Y, Smolders I (2008) Seizure activity and changes in hippocampal extracellular glutamate, GABA, dopamine and serotonin. Epilepsy Res 78:50-59
30. Moojen VK, Martins MR, Reinke A, Feier G, Agostinho FR, Cechin EM, Quevedo J (2006) Effects of milnacipran in animal models of anxiety and memory. Neurochem Res 31:571-577 (Pubitemid 43873753)
31. Morishita S (2009) Clonazepam as a therapeutic adjunct to improve the management of depression: a brief review. Hum Psychopharmacol 24:191-198
32. Pae CU (2009) Pregabalin augmentation to antidepressants in patients with major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 33:577-578
33. Pericic D, Svob Strac D (2007) The role of 5-HT(7) receptors in the control of seizures. Brain Res 1141:48-55 (Pubitemid 46371399)
34. Poirier MF, Galinowski A, Amado I, Longevialle R, Bourdel MC, Tournoux A, Serre C, Loo H (2004) Double-blind comparative study of the action of repeated administration of milnacipran versus placebo on cognitive functions in healthy volunteers. Hum Psychopharmacol 19:1-7 (Pubitemid 38159269)
35. Porecca F, Jiang Q, Tallarida RJ (1990) Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. Eur J Pharmacol 179:463-468 (Pubitemid 20137518)
36. Puozzo C, Panconi E, Deprez D (2002) Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol 17(1):S25-S35
37. Rosenstein DL, Nelson JC, Jacobs SC (1993) Seizures associated with antidepressants: a review. J Clin Psychiatry 54:289-299
38. Salzberg MR, Vajda FJE (2001) Epilepsy, depression and antidepressant drugs. J Clin Neurosci 8:209-215
39. Seethalakshmi R, Krishnamoorthy ES (2007) Depression in epilepsy: phenomenology, diagnosis and management. Epileptic Disord 9:1-10 (Pubitemid 46396670)
40. Sillis MA, Loo PS (1989) Tricyclic antidepressant and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate. Mol Pharmacol 36:160-165
41. Smolders I, Clinckers R, Meurs A, De Bundel D, Portelli J, Ebinger G, Michotte Y (2008) Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action. Neuropharmacology 54:1017-1028
42. Statnick MA, Maring-Smith ML, Clough RW, Wang C, Dailey JW, Jobe PC, Browning RA (1996) Effect of 5, 7-dihydroxytryptamine on audiogenic seizures in genetically epilepsy-prone rats. Life Sci 69:1763-1771 (Pubitemid 26364233)
43. Tran PV, Bymaster FP, McNamara RK, Potter WZ (2003) Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 23:78-86 (Pubitemid 36164428)
44. Treiman DM (2001) GABAergic mechanism in epilepsy. Epilepsia 42 (Suppl. 3):8-12
45. Trimble MR, Meldrum BS, Anlezark G (1977) Effect of nomifensine on brain amines and epilepsy in photosensitive baboons. Br J Clin Pharmacol 4(Suppl 2):101S-107S
46. Tutka P, Mróz T, Klucha K, Piekarczyk M, Wielosz M (2005) Bupropion-induced convulsions: preclinical evaluation of antiepileptic drugs. Epilepsy Res 64:13-22 (Pubitemid 40726161)
47. Ugale RR, Mittal N, Hirani K, Chopde CT (2004) Essentiality of central GABAergic neuroactive steroid allopregnanolone for anticonvulsant action of fluoxetine against pentylenetetrazoleinduced seizures in mice. Brain Res 1023:102-111 (Pubitemid 39195339)
48. Uzbay IT (2008) Serotonergic anti-depressants and ethanol withdrawal syndrome: a review. Alcohol Alcohol 43:15-25
49. Venault P, Chapouthier G, De Carvalho LP, Simiand J, Morre M, Dodd RH, Rossier J (1986) Benzodiazepines impair and beta-carbolines enhance performance in learning and memory tasks. Nature 321:864-866 (Pubitemid 16097728)
50. Vigo DV, Baldessarini RJ (2009) Anticonvulsants in the treatment of major depressive disorder: an overview. Harv Rev Psychiatry 17:231-241
51. Wang C, Mishra PK, Dailey JW, Jobe PC, Browning RA (1994) Noradrenergic terminal fields as determinants of seizure predisposition in GEPR-3s: a neuroanatomic assessment with intracerebral microinjections of 6-hydroxydopamine. Epilepsy Res 18:1-9 (Pubitemid 24159585)
52. Wegener G, Volke V, Harvey BH, Rosenberg R (2003) Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res 959(1):128-134 (Pubitemid 35435413)
53. Weinshenker D, Szot P, Miller NS, Palmiter RD (2001) Alpha(1) and beta(2) adrenoreceptor agonists inhibit pentylenetetrazole-induced seizures in mice lacking norepinephrine. J Pharmacol Exp Ther 298:1042-1048 (Pubitemid 32761920)
54. Weiss M, Blier P, de Montigny C (2007) Effect of long-term administration of the antidepressant drug milnacipran on serotonergic and noradrenergic projections. Exp Neurol 108:136-140
55. Wesolowska A, Nikiforuk A, Chojnacka-Wójcik E (2006) Anticonvulsant effect of the selective 5-HT1B receptor agonist CP 94253 in mice. Eur J Pharmacol 541:57-63 (Pubitemid 44192370)
56. Witkin JM, Baez M, Yu J, Barton ME, Shannon HE (2007) Constitutive deletion of the serotonin-7 (5-HT(7)) receptor decreases electrical and chemical seizure thresholds. Epilepsy Res 75:39-45 (Pubitemid 46856117)
57. Yilmaz I, Sezer Z, Kayir H, Uzbay TI (2007) Mirtazapine does not affect pentylenetetrazole- and maximal electroconvulsive shock-induced seizures in mice. Epilepsy Beh 11:1-5 (Pubitemid 47087198)
58. Zemlan FP, Garver DL (1990) Depression and antidepressant therapy: receptor dynamics. Prog Neuropsychopharmacol Biol Psychiatry 14:503-523